Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141089
Status:
COMPLETED
Last Update Posted:
2008-02-01
First Post:
2005-08-31
Brief Title:
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tegaserod HTF919 is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine 5-HT agonists
The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation
The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None